Queensland COVID-19 research

  • UQ vaccine delivery spinout company achieves global deals on vaccine delivery technology

    October 2020

    The University of Queensland spinout company Vaxxas, that is developing technology based on UQ’s innovative research developed at the Australian Institute for Bioengineering and Nanotechnology, has announced two partnerships that could revolutionise the manufacture and delivery of vaccines. The technology platform that allows vaccines to be administered via a small 1 centimetre squared patch with 5000 little projections that are invisible to the naked eye and prick the skin when applied.
    Merck, a world leader in vaccine development, will access Vaxxas’ HD-MAP technology for the development and manufacture of an undisclosed vaccine. Vaxxas has also announced that German manufacturing equipment maker Harro Höfliger will help Vaxxas develop a high-throughput, aseptic manufacturing line to make vaccine products based their technology — with a goal of eventually churning out millions of vaccine patches a week. In October it was announced that Vaxxas will partner with the US Government to test its needle-free vaccine delivery that could significantly reduce the need for vaccine refrigeration and storage technology.

Artists in Residence Science Program

Art meets science exhibition

  • About the exhibition

    The 2012–2018 Art meets Science Exhibitions provided an opportunity for artists from across South East Queensland to join the artists participating in the Artist in Residence Science program in showcasing their recent artworks that demonstrate a strong art-science connection. Find out more about the artists and artworks featured in these exhibitions in the 2015-2018 Art meets Science exhibition catalogues.

    Therese Flynn-Clarke - Moths of the Caldera - Opodiphthera eucalypti (Gum Emperor Moth) - made from all natural plant fibres